# InMIND (NCT04680052)

> A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

No report yet. It can be ordered.

- Drugs tested: tafasitamab
- Indication: relapsed/refractory follicular lymphoma or marginal zone lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04680052
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Incyte Corporation
- Conditions: Follicular Lymphoma; Marginal Zone Lymphoma
- Interventions: tafasitamab; rituximab; lenalidomide; placebo
- Enrollment: 654
- Primary outcome: FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First
- Primary outcome: FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First

## Indexed commentary on InMIND so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 52
- Podcasts: 25
- X threads: 23
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=inmind-nct04680052

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04680052", "email": "<work email>"}; the inbox owner confirms by the emailed link.